Dimethylaminomicheliolide (DMAMCL) Inhibits Cell Proliferation and Increases Apoptosis and Efficacy of Gemcitabine via Annexin A2 in Pancreatic Adenocarcinoma
Abstract Background: Pancreatic adenocarcinoma is one of the highest malignant tumors in digestive tract with extremely poor survival rate. Dimethylaminomicheliolide (DMAMCL) is a clinical developing anti-cancer agent, however, little is known regarding its effects in pancreatic cancer, and the mechanisms of DMAMCL are still not fully understood.Methods: This study evaluated DMAMCL on three pancreatic cancer cell lines by cell viability assay, colony formation assay, and apoptosis assay. To identify the direct binding target of DMAMCL in pancreatic cells, a chemical proteomics approach, molecular docking and site-directed mutagenesis were performed.Results: DMAMCL inhibits proliferation and promotes apoptosis of pancreatic cancer cells. Interestingly, using a chemical proteomics approach, we identify ANXA2 as a direct binding target of DMAMCL in pancreatic cells. Molecular docking and site-directed mutagenesis confirm that Cys132 (C132) of ANXA2 is the binding site for DMAMCL. The knockdown of ANXA2 largely decreases the inhibition activity of DMAMCL, indicating that the effect of DMAMCL is mainly mediated by ANXA2 in pancreatic cancer. In addition, the combination regimen of gemcitabine and DMAMCL exhibits synergistic effect on pancreatic cancer cell lines at both proliferation and pro-apoptosis level. Conclusions: Thus, our findings elucidate the mechanisms of DMAMCL and may provide a potential strategy to enhancing the efficacy of gemcitabine in pancreatic adenocarcinoma.